Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Bull Exp Biol Med ; 161(5): 657-661, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27709382

ABSTRACT

The therapeutic effect of doxazosin (40 µg/kg/day over one month) on urinary bladder was examined in female rats with modeled chronic infravesical obstruction (IVO) produced by graduated mechanical constriction of the proximal urethral segment. In one month, IVO induced a pronounced vesical hypertrophy both in treated and untreated rats that manifested in increased bladder weight and capacity, the latter increment being pronouncedly greater in treated rats. In untreated IVO rats, infusion cystometry revealed elevated basal intravesical pressure of void bladder P0, markedly increased maximal (premicturitional) pressure Pmax, and increased amplitude of spontaneous oscillations of intravesical pressure ΔPdet in filled bladder. Doxazosin produced no significant effect on Pmax rise during IVO, but prevented elevation of P0 and increment of ΔPdet in filled bladder. During gradual filling of urinary bladder in control (intact) rats, the parasympathetic vesical influences increased progressively, while in untreated IVO rats, the adrenergic influences prevailed even at maximal filling of the bladder. In IVO rats, doxazosin prevented the bias of the sympathetic-parasympathetic balance in the filled bladder in favor of sympathetic influences, but did not prevent this bias in a void bladder. It is hypothesized that α-adrenoblockers improve micturition during IVO caused by benign prostatic hyperplasia not only by decreasing the urethral resistance to urine flow due to down-regulation of prostate smooth muscle tone, but also by a direct action of these blockers on detrusor adrenergic receptors and central structures involved in urinary bladder control.


Subject(s)
Adrenergic alpha-1 Receptor Antagonists/pharmacology , Doxazosin/pharmacology , Urethral Obstruction/drug therapy , Urination/drug effects , Adrenergic alpha-1 Receptor Antagonists/therapeutic use , Animals , Doxazosin/therapeutic use , Drug Evaluation, Preclinical , Female , Male , Organ Size/drug effects , Prostatic Hyperplasia , Rats , Sympathetic Fibers, Postganglionic/drug effects , Sympathetic Fibers, Postganglionic/physiopathology , Urethral Obstruction/physiopathology , Urinary Bladder/drug effects , Urinary Bladder/innervation , Urinary Bladder/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...